Who are GeneLancet Biosciences's investors?

GeneLancet Biosciences's investors include The Innovation Space.

GeneLancet Biosciences

1 known investors

GeneLancet develops proprietary LgRNA technology for precise gene editing, with applications in CRISPR polymerase-directed therapies targeting neurodegenerative diseases and cancers with unmet medical needs.

Biotech Deep Tech Healthtech

Founders & leadership

Sheri Linin

Investors · 1

The Innovation SpaceWilmington · $200K

Competitors · 1

by search overlap

CRISPR4 shared keywordsCRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology. It is led by a management team, board of directors, and scientific founders from the biotech and pharmaceutical industries.

Companies competing with GeneLancet Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2022	$300K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does GeneLancet Biosciences do?: GeneLancet develops proprietary LgRNA technology for precise gene editing, with applications in CRISPR polymerase-directed therapies targeting neurodegenerative diseases and cancers with unmet medical needs.
Who are GeneLancet Biosciences's investors?: GeneLancet Biosciences's investors include The Innovation Space.